Journal Article DKFZ-2026-02004

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Should there be informed decision-making for prostate cancer screening? An analysis of preference sensitivity.

 ;

2026
Sage London [u.a.]

Journal of medical screening nn, nn () [10.1177/09691413261478762]
 GO

Abstract: BackgroundAlmost all national guidelines groups recommend that individual men make an informed personal decision about whether to be screened for prostate cancer. This implies the decision to undergo prostate-specific antigen (PSA) testing is preference sensitive; that is, whether the expected utility of screening is higher or lower than that of no screening can vary depending on a man's preferences ('utilities') for downstream health states such as urinary incontinence.MethodsWe reviewed the literature to find evidence on whether PSA screening is indeed a preference-sensitive decision.ResultsWe found that preference sensitivity was routinely asserted without providing any evidence. Some authors pointed to studies of PSA decision aids, but there is no logical link between a decision aid changing a decision and that decision being preference sensitive. The major modeling study on PSA screening found higher expected utility for PSA screening irrespective of how a man might feel about the side-effects of treatment. One study did find that while PSA screening was generally favored, expected utility was fractionally lower in a small subgroup, but the difference was extremely small, and would not be negative with recent changes to PSA screening pathways.ConclusionThe assumption underlying informed choice policies-PSA screening is a preference-sensitive decision-is not supported by the literature. Men should be provided with clear information about and give consent for PSA testing, but preference elicitation as part of shared decision-making is not indicated.

Keyword(s): PSA screening ; Prostate cancer ; decision analysis ; preference sensitivity ; shared decision making

Classification:

Note: #LA:C070# / epub

Contributing Institute(s):
  1. Klinische Epidemiologie der Krebsfrüherkennung (C070)
Research Program(s):
  1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2026
Database coverage:
Medline ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Ebsco Academic Search ; Essential Science Indicators ; IF < 5 ; JCR ; NationallizenzNationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Public records
Publications database

 Record created 2026-08-13, last modified 2026-08-14



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)